Equities
  • Price (EUR)3.98
  • Today's Change0.16 / 4.19%
  • Shares traded0.00
  • 1 Year change+12.43%
  • Beta--
Data delayed at least 15 minutes, as of Jan 27 2023 20:52 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

  • Revenue in USD (TTM)102.52m
  • Net income in USD51.95m
  • Incorporated1999
  • Employees134.00
  • Location
    Genfit SAParc Eurasante 885 avenue Eugene AvineeLOOS 59120FranceFRA
  • Phone+33 320164000
  • Fax+33 320164001
  • Websitehttps://www.genfit.fr/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GNFT:PAR since
announced
Transaction
value
Versantis AGDeal completed19 Sep 202219 Sep 2022Deal completed-5.69%108.85m
Data delayed at least 15 minutes, as of Jan 27 2023 16:35 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.